ArticleAmerican journal of cancer research2023
Low-dose decitabine plus bortezomib-dexamethasone therapy is well-tolerated and highly effective on first-relapsed multiple myeloma: a single-center phase 2 trial.
Lijie Liang et al.PubMed ↗Full text ↗
No numbers read from the abstract.